Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 9:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 588 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: acetylsalicylic-acid (aspirin) Clear all
Not listed Phase 4 Interventional Accepts healthy volunteers

162 mg of Aspirin for Prevention of Preeclampsia

NCT05221164
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin 162 mg
Drug
Lead sponsor
Methodist Medical Center of Illinois
Other
Eligibility
Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 11, 2026, 9:39 PM EDT
Completed Phase 4 Interventional Results available

Postoperative Pain Control in Septum and Sinus Surgery

NCT04149964
View directory record Official record
Conditions
Post-operative Pain, Sinus Surgery
Interventions
Acetaminophen 325 mg Oral Tablet, Acetaminophen 650 mg Oral Tablet, OxyCODONE 5 mg Oral Tablet, Acetaminophen/Hydrocodone 325 mg/7.5 mg oral tablet
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 11, 2026, 9:39 PM EDT
Completed Not applicable Interventional

Improving Aspirin Use in Diabetes: A Cluster Randomized Trial

NCT00262977
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Electronic prompt plus patient-directed intervention, Electronic prompt to clinician to prescribe aspirin
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
40 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2010 · Synced Oct 11, 2026, 9:39 PM EDT
Completed Phase 4 Interventional

Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial

NCT00343876
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
aspirin, clopidogrel
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 11, 2026, 9:39 PM EDT
Terminated Phase 1 Interventional

Improving Medication Adherence in Post-ACS Patients

NCT00576160
View directory record Official record
Conditions
Medication Adherence, Acute Coronary Syndrome
Interventions
PST therapy
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 11, 2026, 9:39 PM EDT
Recruiting Phase 2 Interventional

IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

NCT03152058
View directory record Official record
Conditions
High Risk Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome in Pregnancy, Lupus Anticoagulant Disorder
Interventions
Certolizumab Pegol
Drug
Lead sponsor
David Ware Branch
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
New York, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 11, 2026, 9:39 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

NCT02504216
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban-Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
6,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
105
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 11, 2026, 9:39 PM EDT
Not listed Phase 4 Interventional

Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy

NCT04059679
View directory record Official record
Conditions
Coronary Artery Disease, Peripheral Artery Disease
Interventions
Rivaroxaban 2.5 Mg Oral Tablet, Aspirin 81 mg
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 11, 2026, 9:39 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

NCT03805932
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience, Dexamethasone, Acetaminophen, Diphenhydramine, Famotidine, Aspirin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 11, 2026, 9:39 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

NCT07762716
View directory record Official record
Conditions
Glioblastoma (GBM)
Interventions
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Temozolomide (TMZ), Losartan and aspirin
Drug
Lead sponsor
BreakBio Corp
Industry
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 11, 2026, 9:39 PM EDT
Terminated Not applicable Interventional Results available

Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia

NCT00719537
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin, Placebo Oral Tablet, Progesterone
Drug
Lead sponsor
John Uckele
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 11, 2026, 9:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Aspirin and Clopidogrel Reactivity in Patients With Critical Limb Ischemia (CLI)

NCT02094755
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Blood draw only
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 11, 2026, 9:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Platelet Function and Safety After IV and Oral Diclofenac, IV Ketorolac and Oral Aspirin in Adult Volunteers

NCT00548678
View directory record Official record
Conditions
Healthy
Interventions
intravenous diclofenac sodium (DIC075V), ketorolac, oral diclofenac (Cataflam), aspirin
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jul 16, 2008 · Synced Oct 11, 2026, 9:39 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

NCT02164864
View directory record Official record
Conditions
Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions
Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin, Dabigatran Etexilate 150mg, Clopidogrel or Ticagrelor, Warfarin 5mg, Warfarin 1mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
45
States / cities
Birmingham, Alabama • Cottonwood, Arizona • Mesa, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 11, 2026, 9:39 PM EDT
Completed Phase 3 Interventional

Warfarin and Antiplatelet Therapy in Chronic Heart Failure

NCT00007683
View directory record Official record
Conditions
Heart Failure
Interventions
Warfarin titrated to an INR of 2.5-3.0, Aspirin, Clopidogrel 75
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 11, 2026, 9:39 PM EDT
Completed Phase 4 Interventional Results available

Clopidogrel Monotherapy in Patients With High Bleeding Risk

NCT05223335
View directory record Official record
Conditions
Bleeding Complications
Interventions
Clopidogrel, Prasugrel, Tricagrelor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 11, 2026, 9:39 PM EDT
Completed Phase 1 Interventional Results available

Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions

NCT01241903
View directory record Official record
Conditions
Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
Interventions
rosuvastatin, placebo
Drug
Lead sponsor
Susan Smyth
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 11, 2026, 9:39 PM EDT
Completed Phase 2 Interventional Results available

LIPS-A: Lung Injury Prevention Study With Aspirin

NCT01504867
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Aspirin, Lactose powder
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
16
States / cities
Stanford, California • Bridgeport, Connecticut • Gainsville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 11, 2026, 9:39 PM EDT
Completed Phase 3 Interventional Results available

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

NCT01259856
View directory record Official record
Conditions
High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
Interventions
PEGASYS, Hydroxyurea, Aspirin
Drug
Lead sponsor
Ronald Hoffman
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 11, 2026, 9:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Interaction Study To Assess the Effect of Food on the Pharmacokinetics of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg

NCT01163630
View directory record Official record
Conditions
Effect of Food, Pharmacokinetics
Interventions
esomeprazole/ASA Fixed Dose Combination (FDC)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Oveland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Oct 11, 2026, 9:39 PM EDT
Completed Not applicable Interventional Results available

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

NCT02409680
View directory record Official record
Conditions
Premature Birth
Interventions
Low dose aspirin, Placebo
Drug
Lead sponsor
NICHD Global Network for Women's and Children's Health
Network
Eligibility
18 Years to 40 Years · Female only
Enrollment
11,976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • Denver, Colorado • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 11, 2026, 9:39 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets

NCT03787927
View directory record Official record
Conditions
Bleeding, Platelet Dysfunction Due to Drugs, Platelet Dysfunction
Interventions
Autologous Platelet Transfusion (room-temperature-stored), Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (cold-stored 15 days), Aspirin, Clopidogrel
Drug
Lead sponsor
Bloodworks
Other
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 11, 2026, 9:39 PM EDT
Completed Not applicable Interventional

A Pilot Study Examining the Efficacy of Biomodulator Treatment for Chronic Low Back Pain

NCT02707094
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Biomodulator, Usual Care (Medication + Exercise)
Device · Other
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 62 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 11, 2026, 9:39 PM EDT
Recruiting Early Phase 1 Interventional

Daily Aspirin Treatment After Preeclampsia

NCT06168461
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 11, 2026, 9:39 PM EDT